Literature DB >> 8383153

Calcitonin, as SMS 201-995, ameliorates the VIPoma syndrome.

A Antonelli1, C Gambuzza, F Bertoni, L Baschieri.   

Abstract

A 72-year-old woman was referred to our hospital for diarrhea, abdominal and back pain, weight loss, low serum potassium level. Pathological findings and high circulating Vasoactive Intestinal Peptide (VIP) levels allowed us to diagnose "VIPoma syndrome". The patient underwent a treatment with SMS 201-995 with improvement of symptomatology and reduction of circulating VIP levels. After a wash-out period the patient was treated with salmon calcitonin with a net improvement of diarrhea, normalization of potassium serum level and reduction of VIP level. The symptomatology recurred after calcitonin withdrawal. These data confirm the effectiveness of SMS 201-995 in the VIPoma syndrome and suggest that calcitonin may ameliorate symptomatology and reduce circulating VIP level in patients with VIPoma tumor.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8383153     DOI： 10.1007/bf03345831

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


  19 in total

1.  Effect of salmon calcitonin on symptoms and urinary excretion of 5 hydroxyindoleacetic acid in the carcinoid syndrome.

Authors:  A Antonelli; P Del Guerra; A Fierabracci; E Gori; L Baschieri
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-17

2.  Calcitonin inhibition of gastrin secretion in man.

Authors:  T Oyama; M Shiraki; H Ito; K Tanaka; H Orimo
Journal:  Endocrinol Jpn       Date:  1973-12

3.  Inhibitory effect of calcitonin on growth hormone and insulin secretion in man.

Authors:  L Cantalamessa; A Catania; E Reschini; M Peracchi
Journal:  Metabolism       Date:  1978-08       Impact factor: 8.694

4.  Calcitonin in extrathyroidal tissues of man.

Authors:  K L Becker; R H Snider; C F Moore; K G Monoghan; O L Silva
Journal:  Acta Endocrinol (Copenh)       Date:  1979-12

5.  Stimulation of gastrin secretion in the pig by parathyroid hormone and its inhibition by thyrocalcitonin.

Authors:  R M Bolman; C W Cooper; S C Garner; P L Munson; S A Wells
Journal:  Endocrinology       Date:  1977-04       Impact factor: 4.736

6.  Influence of calcitonin on serum levels of pancreatic polypeptide in man.

Authors:  W Petritsch; G Leb; A Passath; R Goebel; H Pristautz
Journal:  Z Gastroenterol       Date:  1985-03       Impact factor: 2.000

7.  Treatment of the carcinoid syndrome with somatostatin, salmon calcitonin, or octreotide.

Authors:  A Antonelli; C Gambuzza; F Bertoni; L Baschieri
Journal:  Clin Ther       Date:  1992 Mar-Apr       Impact factor: 3.393

8.  Morphologic patterns and diagnostic criteria of VIP-producing endocrine tumors. A histologic, histochemical, ultrastructural, and biochemical study of 32 cases.

Authors:  C Capella; J M Polak; R Buffa; F J Tapia; P Heitz; L Usellini; S R Bloom; E Solcia
Journal:  Cancer       Date:  1983-11-15       Impact factor: 6.860

9.  Calcitonin gene-related peptide stimulates somatostatin release from isolated perfused rat stomach.

Authors:  T Yamatani; S Kadowaki; T Chiba; H Abe; K Chihara; M Fukase; T Fujita
Journal:  Endocrinology       Date:  1986-05       Impact factor: 4.736

10.  Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy.

Authors:  L K Kvols
Journal:  Am J Med       Date:  1986-12-22       Impact factor: 4.965
View more
  1 in total

Review 1.  Pancreatic VIPomas: subject review and one institutional experience.

Authors:  Amir A Ghaferi; Karen A Chojnacki; William D Long; John L Cameron; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2008-02       Impact factor: 3.452
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.